Assignee
DECIPHER BIOSCIENCES INC
US·7 granted patents·7 pending applications·31 citations·filing 2012–2022
Top patents by PatentIndex Score
14 records- 0191US10865452B2Systems and methods for expression-based discrimination of distinct clinical disease states in prostate cancerDECIPHER BIOSCIENCES INC·Filed 2016·Granted Dec 15, 2020·7 cites·14 claims
- 0287US10513737B2Cancer diagnostics using non-coding transcriptsDECIPHER BIOSCIENCES INC·Filed 2012·Granted Dec 24, 2019·9 cites·7 claims
- 0384US11208697B2Molecular subtyping, prognosis, and treatment of bladder cancerDECIPHER BIOSCIENCES INC·Filed 2018·Granted Dec 28, 2021·5 cites·11 claims
- 0484US11078542B2Genetic signatures to predict prostate cancer metastasis and identify tumor aggressivenessDECIPHER BIOSCIENCES INC·Filed 2018·Granted Aug 3, 2021·3 cites·3 claims
- 0582US11414708B2Use of genomic signatures to predict responsiveness of patients with prostate cancer to post-operative radiation therapyDECIPHER BIOSCIENCES INC·Filed 2017·Granted Aug 16, 2022·3 cites·9 claims
- 0667US2022349011A1Cancer diagnostics using biomarkersDECIPHER BIOSCIENCES INC·Filed 2021·Application pending·0 cites
- 0766US11035005B2Cancer diagnostics using biomarkersDECIPHER BIOSCIENCES INC·Filed 2013·Granted Jun 15, 2021·4 cites·14 claims
- 0866US2022177974A1Genetic signatures to predict prostate cancer metastasis and identify tumor aggressivenessDECIPHER BIOSCIENCES INC·Filed 2021·Application pending·0 cites
- 0965US2022325352A1Molecular subtyping, prognosis, and treatment of bladder cancerDECIPHER BIOSCIENCES INC·Filed 2021·Application pending·0 cites
- 1059US2024002944A1Methods and genomic classifiers for identifying homologous recombination deficiency prostate cancerDECIPHER BIOSCIENCES INC·Filed 2021·Application pending·0 cites
- 1157US2024319192A1Use of immune content scores diagnostically to predict responsiveness of prostate cancer patients to immunotherapyDECIPHER BIOSCIENCES INC·Filed 2022·Application pending·0 cites
- 1254US2023115828A1Genomic classifiers for prognosing and treating clinically aggressive luminal bladder cancerDECIPHER BIOSCIENCES INC·Filed 2021·Application pending·0 cites
- 1351US2022213557A1Non-coding rna for subtyping of bladder cancerDECIPHER BIOSCIENCES INC·Filed 2020·Application pending·0 cites
- 1445US12497660B2Use of immune cell-specific gene expression for prognosis of prostate cancer and prediction of responsiveness to radiation therapyDECIPHER BIOSCIENCES INC·Filed 2018·Granted Dec 16, 2025·0 cites·19 claims
Counts cover granted patents and pending applications in the PatentIndex corpus. How scoring works →